Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 2/20 | 0.31 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.31 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.31 |
| ▸ | NMT2 | O60551 | 1/20 | 0.30 |
| ▸ | NMT1 | P30419 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20094872 | 0.92 | — | — | |
| SCHEMBL16572076 | 0.89 | SIRT6 (0.37) | TLR2SIRT6SIRT1NMT2NMT1 | |
| SCHEMBL16572335 | 0.80 | NPY1R (0.31) | — | |
| SCHEMBL19366157 | 0.70 | NPY4R (0.33) | TLR2SIRT6SIRT1 | |
| SCHEMBL16572077 | 0.67 | GNAI3 (0.57) | TLR2SIRT6SIRT1 | |
| SCHEMBL16572290 | 0.67 | GNAI3 (0.59) | TLR2SIRT6SIRT1 | |
| SCHEMBL16572280 | 0.67 | GNAI3 (0.59) | TLR2SIRT6SIRT1 | |
| SCHEMBL11740613 | 0.66 | FOLH1 (0.44) | — | |
| SCHEMBL4752594 | 0.66 | FOLH1 (0.44) | — | |
| SCHEMBL16572301 | 0.63 | GNAI3 (0.51) | TLR2SIRT6SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180111907-A1 | DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND OTHER MUCOSAL DISEASES | PARION SCIENCES, INC. | 2018-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180111907-A1 | DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND OTHER MUCOSAL DISEASES | SCNN1B, SCNN1A, SCNN1G | TLR2 262/4885SIRT6 1201/4885SIRT1 818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.